target audience: TECH BUYER Publication date: Dec 2022 - Document type: IDC Perspective - Doc Document number: # US49893022
Medidata NEXT 2022: Solving the Impossible
Content
List of Figures
Get More
When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.
Related Links
Abstract
This IDC Perspective reviews the industry analyst event recently hosted by Medidata (a Dassault Systemes [DS] company) from November 15 to 16, 2022, in New York. It was addressed by Life Sciences and Healthcare Sector Board Chairman, DS, Tarek Sherif; co-CEOs of Medidata (Rama Kondru and Sastry Chilukuri); and the CEO of Patient Cloud (Anthony Costello), as well as Medidata's leadership, partners, and customers who outlined the new offerings and the strategic road map for Medidata in life sciences.
"As technology adoption continues to scale rapidly in the life sciences industry, the industry and technology providers continue to innovate; pharmas and biotechs are looking for solutions that will drive quality and compliance, accelerate time to market, and weave in both a site-centric and a patient-centric focus. Technology solutions that power decentralized clinical trials, that drive diversity and equity, that improve access, that integrate a risk-based quality management strategy, and that drive interoperability will serve as differentiators and define the pace of innovation for the life sciences industry," says Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology at IDC Health Insights.
"Consolidated clinical trial results, augmented by real-world data and patient and provider insights, can help construct rich patient journey experiences that help life sciences companies and healthcare providers find patients who can benefit from innovative therapies and result in improved health outcomes and better knowledge sharing between researchers, medical affairs experts, providers, and patients," says Michael Townsend, research director, Life Sciences Commercial Strategies at IDC Health Insights.